• 3 August 2018

    JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced initiation of patient enrollment in the Early Feasibility Study (EFS) of its next generation JenaValve Pericardial TAVR System using the Everdur™ transcatheter heart valve (THV) and CoronatixTM Transfemoral Delivery Catheter at NewYork-Presbyterian/ Columbia University Medical Center (CUMC), New York City, and MedStar Washington Hospital Center, Washington, DC. The EFS is investigating the JenaValve Pericardial TAVR System for the minimally invasive treatment of patients with symptomatic, severe aortic stenosis (AS) and symptomatic, severe aortic regurgitation (AR) for whom open surgery is an extreme or high risk. The JenaValve Pericardial TAVR System is an investigational device in the United States and internationally.

  • 31 July 2018

    Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that the United States National Institutes of Health (NIH) has awarded an $8.9 million grant (1) to Professor Victor Thannickal at the University of Alabama at Birmingham (UAB) to fund a multi-year research program evaluating the role of NOX enzymes in idiopathic pulmonary fibrosis (IPF), a chronic lung disease that results in fibrosis of the lungs. The core component of the program will be to conduct a 24-week Phase 2 trial of the Company’s lead product candidate, GKT831, in patients with IPF.

  • 25 July 2018

    Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today provides a business update, including progress around the ongoing Phase 2 study of GKT831 in Primary Biliary Cholangitis (PBC), and reports cash and cash equivalents of €9.3 million, on June 30, 2018. 

  • 16 July 2018

    Immunocore Limited, a leading T cell receptor (TCR) company focused on delivering first-in-class biological therapies that have the potential to transform lives, today announces that Paul Fry will step down from his position of Chief Financial Officer on 26 October 2018.  Paul will join Vectura Group PLC, the FTSE listed industry-leading inhaled product formulation, device design and development business, as Chief Financial Officer and Executive Board Member.  Immunocore is recruiting a successor and hopes to be able to provide an update in due course. Paul will help support a managed transition.

  • 9 July 2018

    Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, announced today that it has received the CE mark for its Sacral Neuromodulation External Trial System.